logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 8993619 B1

PDFFull Text
Date of Patent:
Mar. 31, 2015

Filed:

Apr. 26, 2013

Cyclic bridgehead ether dgat1 inhibitors

Applicants:

Sejal Patel, Lexington, MA (US);

Justin Mao, North Reading, MA (US);

Qian Liu, Malden, MA (US);

Rui Zheng, Chestnut Hill, MA (US);

Tyler Harrison, Somerville, MA (US);

Rohit Duvadie, Arlington, MA (US);

Xin Chen, Lexington, MA (US);

Frederic Zecri, Brookline, MA (US);

Jay Larrow, Cambridge, MA (US);

Xuchun Zheng, Changshu, CN;

Yizong Zhou, Changshu, CN;

Jiong YE, Changshu, CN;

Yiping Ding, Changshu, CN;

Yu Gai, Changshu, CN;

Inventors:

Sejal Patel, Lexington, MA (US);

Justin Mao, North Reading, MA (US);

Qian Liu, Malden, MA (US);

Rui Zheng, Chestnut Hill, MA (US);

Tyler Harrison, Somerville, MA (US);

Rohit Duvadie, Arlington, MA (US);

Xin Chen, Lexington, MA (US);

Frederic Zecri, Brookline, MA (US);

Jay Larrow, Cambridge, MA (US);

Xuchun Zheng, Changshu, CN;

Yizong Zhou, Changshu, CN;

Jiong Ye, Changshu, CN;

Yiping Ding, Changshu, CN;

Yu Gai, Changshu, CN;

Assignee:

Novartis AG, Basel, CH;

Attorney:

Joshua Roth

Primary Examiner:

Kendra D Carter

Int. Cl.
CPC ...
A01N 43/08 (2006.01); A61K 31/34 (2006.01); A01N 43/16 (2006.01); A61K 31/35 (2006.01); A61K 31/505 (2006.01); A01N 43/40 (2006.01); A61K 31/44 (2006.01); A01N 43/82 (2006.01); A61K 31/41 (2006.01); A01N 43/76 (2006.01); A61K 31/42 (2006.01); C07D 401/00 (2006.01); C07D 403/00 (2006.01); C07D 405/00 (2006.01); C07D 411/00 (2006.01); C07D 413/00 (2006.01); C07D 417/00 (2006.01); C07D 419/00 (2006.01); C07D 285/12 (2006.01); C07D 285/14 (2006.01); C07D 513/00 (2006.01); C07D 271/10 (2006.01); C07D 271/12 (2006.01); C07D 498/00 (2006.01); C07D 263/00 (2006.01); C07D 263/34 (2006.01); C07D 493/08 (2006.01); A61K 31/422 (2006.01); A61K 31/4245 (2006.01); A61K 31/433 (2006.01); A61K 31/4439 (2006.01); A61K 31/506 (2006.01); A61K 45/06 (2006.01); C07D 413/12 (2006.01); C07D 417/12 (2006.01);
U.S. Cl.
CPC ...
C07D 493/08 (2013.01); A61K 31/422 (2013.01); A61K 31/4245 (2013.01); A61K 31/433 (2013.01); A61K 31/4439 (2013.01); A61K 31/506 (2013.01); A61K 45/06 (2013.01); C07D 413/12 (2013.01); C07D 417/12 (2013.01);
Abstract

The invention relates to compounds of formula (I): useful for treating disorders mediated by acyl coA-diacylglycerol acyl transferase 1 (DGAT1), e.g. metabolic disorders. The invention also provides methods of treating such disorders, and compounds and compositions etc. for their treatment.

Find Patent Forward Citations

Loading…